Migraine is a common neurologic disorder with clinical phenotypes encompassing a variety of symptoms which all contribute to the burden felt by patients. In addition to negative impacts on a patient’s quality of life, migraine has both direct medical costs and indirect costs related to missed work and decreased productivity that affect individuals as well as society at large. Unfortunately, migraine diagnoses are often missed, and many patients do not receive appropriate treatment. Primary care providers are in a key position to provide timely diagnosis and effectively manage migraine for many patients. This review aims to be a guide for improving migraine management in the primary care setting by providing strategies to overcome common challenges in migraine diagnosis; summarizing current knowledge on the mechanism of action, efficacy, and safety of calcitonin gene–related peptide (CGRP) pathway-targeting therapies; and reviewing approaches to incorporate traditional and emerging treatment options into a patient-centric migraine management strategy.
StovnerLJNicholsESteinerTJ, et al.Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol2018; 17(11): 954–976.
2.
BurchRCLoderSLoderE, et al.The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache2015; 55(1): 21–34.
3.
SteinerTJJensenRKatsaravaZ, et al.Aids to management of headache disorders in primary care (2nd edition). The J Headache Pain2019; 20(1): 57. DOI: 10.1186/s10194-018-0899-2 (accessed 16 August 2021).
4.
DiamondSBigalMESilbersteinS, et al.Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American migraine prevalence and prevention study. Headache2007; 47(3): 355–363.
LucasCGéraudGValadeD, et al.Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache2006; 46(5): 715–725.
7.
Headache Classification Committee of the International Headache Society. Headache classification committee of the international headache society (IHS) the international classification of headache disorder s, 3rd edition. Cephalalgia2018; 38(1): 1–211.
8.
LiptonRBBigalMEDiamondM, et al.Migraine prevalence, disease burden, and the need for preventive therapy. Neurology2007; 68(5): 343–349.
9.
KarsanNGoadsbyPJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol2018; 14(12): 699–710.
10.
CuvellierJCMarsAValléeL. The prevalence of premonitory symptoms in paediatric migraine: a questionnaire study in 103 children and adolescents. Cephalalgia2009; 29(11): 1197–1201.
11.
LaurellKArttoVBendtsenL, et al.Premonitory symptoms in migraine: a cross-sectional study in 2714 persons. Cephalalgia2016; 36(10): 951–959.
12.
EvansRW. The clinical features of migraine with and without aura. Pract Neurol2014; 26–32.
LeonardiMRaggiA. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain2019; 20(1): 41. DOI: 10.1186/s10194-019-0993-0 (accessed 16 August 2021).
17.
BuseDCFanningKMReedML, et al.Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache2019; 59(8): 1286–1299.
18.
YucelAThachAKumarS, et al.Estimating the economic burden of migraine on US employers. Am J Manag Care2020; 26(12): e403–408.
19.
FejesEFeherGGurdanZ, et al.Characteristics of patients referred to a specialized headache clinic. Scientific Rep2020; 10(1): 1146, DOI: 10.1038/s41598-020-58234-w (accessed 16 August 2021).
20.
MafiJNEdwardsSTPedersenNP, et al.Trends in the ambulatory management of headache: analysis of NAMCS and NHAMCS data 1999–2010. J Gen Intern Med2015; 30(5): 548–555.
21.
BuseDCReedMLFanningKM, et al.Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain2020; 21(1): 23, DOI: 10.1186/s10194-020-1084-y (accessed 16 August 2021).
22.
MinenMTBegasse De DhaemOKroon Van DiestA, et al.Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry2016; 87(7): 741–749.
23.
Torres-FerrúsMUrsittiFAlpuenteA, et al.From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain2020; 21(1): 42, DOI: 10.1186/s10194-020-01111-8 (accessed 16 August 2021).
24.
LiptonRBSerranoDHollandS, et al.Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache2013; 53(1): 81–92.
25.
DodickDWLoderEWManack AdamsA, et al.Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache2016; 56(5): 821–834.
26.
VianaMSancesGGhiottoN, et al.Variability of the characteristics of a migraine attack within patients. Cephalalgia2016; 36(9): 825–830.
27.
MartinsIPGouveiaRGParreiraE. Kinesiophobia in migraine. J Pain2006; 7(6): 445–451.
28.
SilbersteinSD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache1995; 35(7): 387–396.
EvansRWSeifertTKailasamJ, et al.The use of questions to determine the presence of photophobia and phonophobia during migraine. Headache2008; 48(3): 395–397.
31.
KelmanL. Migraine pain location: a tertiary care study of 1283 migraineurs. Headache2005; 45(8): 1038–1047.
32.
LaiTHFuhJLWangSJ. Cranial autonomic symptoms in migraine: characteristics and comparison with cluster headache. J Neurol Neurosurg Psychiatr2009; 80(10): 1116–1119.
33.
LiptonRBDodickDSadovskyR, et al.A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology2003; 61(3): 375–382.
34.
KatoYPohWHorvathZ, et al.Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users. BMC Neurol2021; 21(1): 345. DOI: 10.1186/s12883-021-02378-3 (accessed 24 January 2022).
LiptonRBHahnSRCadyRK, et al.In-office discussions of migraine: results from the American Migraine Communication Study. J Gen Intern Med2008; 23(8): 1145–1151.
37.
BuseDCRupnowMFLiptonRB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc2009; 84(5): 422–435.
38.
EigenbrodtAKAshinaHKhanS, et al.Diagnosis and management of migraine in ten steps. Nat Rev Neurol2021; 17(8): 501–514.
39.
QutubWNMagharbelRSAdhamSW, et al.Prevalence and determinants of tension headache among medical students during their clinical years at King Abdulaziz University in Jeddah, 2019. J Community Health Manag2020; 7(1): 14–21.
40.
MartinVTFeoktistovASolomonGD. A rational approach to migraine diagnosis and management in primary care. Ann Med2021; 53(1): 1979–1990.
41.
SprengerTVianaMTassorelliC. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics2018; 15(2): 313–323.
42.
MohantyDLippmannS. CGRP inhibitors for migraine. Innov Clin Neurosci2020; 17(4–6): 39–40.
43.
AilaniJBurchRCRobbinsMS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache2021; 61(7): 1021–1039.
44.
SilbersteinSDHollandSFreitagF, et al.Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults; report of the quality standards subcommittee of the American academy of neurology and the American Headache Society. Neurology2012; 78(17): 1337–1345.
45.
GalesBJBaileyEKReedAN, et al.Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother2010; 44(2): 360–366.
46.
SchumacherHManciaG. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl2008; 1: 32–40.
47.
GoadsbyPJEdvinssonLEkmanR. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol1990; 28(2): 183–187.
48.
LassenLHHaderslevPAJacobsenVB, et al.CGRP may play a causative role in migraine. Cephalalgia2002; 22(1): 54–61.
49.
HansenJMHaugeAWOlesenJ, et al.Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia2010; 30(10): 1179–1186.
50.
EdvinssonLHaanesKAWarfvingeK, et al.CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol2018; 14(6): 338–350.
51.
PellesiLGuerzoniSPiniLA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev2017; 6(6): 534–547.
52.
IyengarSJohnsonKWOssipovMH, et al.CGRP and the trigeminal system in migraine. Headache2019; 59(5): 659–681.
53.
AshinaM. Migraine. New Engl J Med2020; 383(19): 1866–1876.
54.
CroopRGoadsbyPJStockDA, et al.Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet2019; 394(10200): 737–745.
55.
LiptonRBDodickDWAilaniJ, et al.Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA2019; 322(19): 1887–1898.
56.
GoadsbyPJDodickDWAilaniJ, et al.Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol2020; 19(9): 727–737.
57.
CroopRLiptonRBKudrowD, et al.Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet2021; 397(10268): 51–60.
CharlesAPozo-RosichP. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet2019; 394(10210): 1765–1774.
61.
AshinaMGoadsbyPJReuterU, et al.Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol2021; 28(5): 1716–1725.
62.
GoadsbyPJSilbersteinSDYeungPP, et al.Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology2020; 95(18): e2487–e2499.
63.
HirataKTakeshimaTSakaiF, et al.A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf2021; 20(6): 721–733.
64.
SilbersteinSDiamondMHindiyehNA, et al.Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain2020; 21(1): 120. DOI: 10.1186/s10194-020-01186-3 (accessed 16 August 2021).
TepperSJ. CGRP and headache: a brief review. Neurol Sci2019; 40(1): 99–105.
67.
CroopRBermanGKudrowD, et al.Long-Term safety of rimegepant 75 mg for the acute treatment of migraine (study 201) (4829). Neurology2020; 94(15): 4829, https://n.neurology.org/content/94/15_Supplement/4829 (accessed 16 August 2021).
68.
AilaniJLiptonRBHutchinsonS, et al.Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache2020; 60(1): 141–152.
69.
AshinaMGoadsbyPJReuterU, et al.Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia2019; 39(11): 1455–1464.
BeckerWJFindlayTMogaC, et al.Guideline for primary care management of headache in adults. Can Fam Physicia2015; 61(8): 670–679.
73.
DahlöfCG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials. Cephalalgia2006; 26(2): 98–106.
74.
HeppZDodickDWVaronSF, et al.Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia2017; 37(5): 470–485.
75.
WoolleyJMBonafedeMMMaieseBA, et al.Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache2017; 57(9): 1399–1408.
HaHGonzalezA. Migraine headache prophylaxis. Am Fam Physician2019; 99(1): 17–24.
78.
CottrellCKDrewJBWallerSE, et al.Perceptions and needs of patients with migraine: a focus group study. J Fam Pract2002; 51(2): 142–147.
79.
RobbinsMS. Diagnosis and management of headache: a review. JAMA2021; 325(18): 1874–1885.
80.
MoissetXPereiraBCiampi de AndradeD, et al.Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain2020; 21(1): 142. DOI: 10.1186/s10194-020-01204-4 (accessed 24 January 2022).
81.
LiYXXiaoXLZhongDL, et al.Effectiveness and safety of acupuncture for migraine: an overview of systematic reviews. Pain Res Manag2020; 2020: 3825617–3825714. DOI: 10.1155/2020/3825617 (accessed 24 January 2022).
82.
Da SilvaAN. Acupuncture for migraine prevention. Headache2015; 55(3): 470–473.
StarlingAJDodickDW. Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clin Proc2015; 90(3): 408–414.
85.
KelmanL. The triggers or precipitants of the acute migraine attack. Cephalalgia2007; 27(5): 394–402.
86.
Andress-RothrockDKingWRothrockJ. An analysis of migraine triggers in a clinic-based population. Headache2010; 50(8): 1366–1370.
87.
RobbleeJStarlingAJ. SEEDS for success: lifestyle management in migraine. Cleve Clin J Med2019; 86(11): 741–749.
88.
KleiboerASorbiMMérelleS, et al.Utility and preliminary effects of online digital assistance (ODA) for behavioral attack prevention in migraine. Telemed J E Health2009; 15(7): 682–690.
Abu-ArafehIRazakSSivaramanB, et al.Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol2010; 52(12): 1088–1097.
91.
OrrSLKabboucheMAO'BrienHL, et al.Paediatric migraine: evidence-based management and future directions. Nat Rev Neurol2018; 14(9): 515–527.
92.
El-ChammasKKeyesJThompsonN, et al.Pharmacologic treatment of pediatric headaches: a meta-analysis. JAMA Pediatr2013; 167(3): 250–258.
93.
PowersSWCoffeyCSChamberlinLA, et al.Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med2017; 376(2): 115–124.
94.
AllaisGChiarleGSinigagliaS, et al.Treating migraine with contraceptives. Neurol Sci2017; 38(1): 85–89.
95.
OngJJYDe FeliceM. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics2018; 15(2): 274–290.
96.
AmundsenSNordengHNezvalová-HenriksenK, et al.Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol2015; 11(4): 209–219.
97.
DeeksED. Atogepant: First Approval. Drugs2022; 82(1): 65–70.
